DPYD polymorphisms in Native populations from the Brazilian Amazon: the absence of the variants in currently recommended clinical genotyping panels

Absence of CPIC-recommended *DPYD* variants in Yanomami and Munduruku indigenous populations of Brazil

A study genotypes clinically relevant DPYD variants (rs3918290, rs55886062, rs67376798, rs75017182) in Yanomami and Munduruku indigenous populations of the Brazilian Amazon (>90% indigenous ancestry). Results show near-complete absence of these variants in these populations, revealing a major gap in current CPIC genotyping panels for this ethnic group. These data have direct implications for fluoropyrimidine dosing (5-FU, capecitabine) if these populations access oncological treatments.

Synthesis written by Geno'X. For the full original abstract, please refer to the source publication.

This study perfectly illustrates the equity problem in pharmacogenetics: DPYD genotyping panels were developed on European populations and fail to capture variants prevalent in other groups. The implication for fluoropyrimidine safety in underrepresented indigenous populations is direct. A strong argument for diversifying CPIC reference panels.